Document is current
Any future updates will be listed below
-
Authors
Seta, Takeshi https://orcid.org/0000-0002-3057-6284
Nakamura, Shohei https://orcid.org/0009-0001-2855-721X
Oura, Mitsuaki https://orcid.org/0000-0002-4907-4647
Yokoyama, Kazuki https://orcid.org/0009-0003-5730-1066
Nishikawa, Yoshitaka https://orcid.org/0000-0003-3313-1990
Hoshino, Nobuaki https://orcid.org/0000-0002-7171-8971
Ninomiya, Kiichiro https://orcid.org/0000-0002-2134-2865
Shimoi, Tatsunori https://orcid.org/0000-0002-3603-8575
Hotta, Katsuyuki https://orcid.org/0000-0002-0112-0843
Nakayama, Takeo https://orcid.org/0000-0002-7918-6252
- License Information
-
More Information
Article History
Received: 30 December 2024
Accepted: 23 March 2025
First Online: 6 May 2025
Declarations
:
: Dr. Hotta reports honoraria from AstraZeneca, Chugai, Lilly, MSD, BMS, Ono, Boehringer Ingelheim, NipponKayaku, Amgen, Taiho, and Merck, and research grants from MSD, AstraZeneca, Chugai, Lilly, BMS, Abbvie, and Ono. Dr. Nakayama reports personal fees from Pharmaceutical Co.; Johnson & Johnson K.K.; AstraZeneca plc; Nippon Zoki Pharmaceutical Co., Ltd.; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Pfizer Japan Inc.; MSD K.K.; Chugai Pharamaceutical Co.; Takeda Pharmaceutical Co.; Janssen Pharmaceutical K.K.; Boehringer Ingelheim International GmbH.; Eli Lilly Japan K.K.; Maruho Co., Ltd.; Mitsubishi Tanabe Pharma Co.; Novartis Pharma K.K.; Allergan Japan K.K.; Novo Nordisk Pharma Ltd.; TOA EIYO Ltd.; AbbVie Inc.; ONO PHARMACEUTICAL CO., LTD.;GSK plc; Alexion Pharmaceuticals, Inc.; Cannon Medical Systems Co.; Kowa Company, Limited; Araya; Merck Co.; Amicus Therapeutics, Inc.; Merck Co.; stock options: BonBon inc.; donation: CancerScan; JMDC Inc. All of them were outside the submitted work. Other authors have stated explicitly that there are no conflicts of interest in connection with this article.
